Di Meglio, Antonio
Martin, Elise
Crane, Tracy E.
Charles, Cecile
Barbier, Aude
Raynard, Bruno
Mangin, Anthony
Tredan, Olivier
Bouleuc, Carole
Cottu, Paul H.
Vanlemmens, Laurence
Segura-Djezzar, Carine
Lesur, Anne
Pistilli, Barbara
Joly, Florence
Ginsbourger, Thomas
Coquet, Bernadette
Pauporte, Iris
Jacob, Guillemette
Sirven, Aude
Bonastre, Julia
Ligibel, Jennifer A.
Michiels, Stefan
Vaz-Luis, Ines
Funding for this research was provided by:
Institut National du Cancer (RISP 2018-13684)
Susan G. Komen (CCR17483507)
Conquer Cancer Foundation (Career Pathway Grant in Symptom Management)
Article History
Received: 20 November 2020
Accepted: 7 February 2022
First Online: 4 March 2022
Declarations
:
: The protocol of the MEDEA Study was approved by the Institutional Scientific Committee for Therapeutic Trials (Commission Scientifique des Essais Thérapeutiques [CSET]) at Gustave Roussy in September 2019 and by the French National Ethics Committee (Comités de protection des personnes [CPP]) in February 2020, with an amendment in July 2020. Each participant should understand, sign, and date the written informed consent form prior to any protocol-specific procedures. Protocol version: version N°2.0 dated 29 July 2020.
: Not applicable.
: The authors declare that they have no competing interests.